SELLAS Life Sciences Group, Inc. announced the immediate exercise of warrants to purchase shares of its common stock, raising $23.6 million in gross cash proceeds.
In exchange for the exercise of the warrants, the investor will receive new unregistered warrants.
The closing of the transaction is expected to occur on or about September 12, 2025.
Gross Proceeds
Approximately $23.6 million raised through the exercise of warrants.
New Warrants Details
New unregistered warrants to purchase up to 19,685,040 shares at an exercise price of $1.88.
Financial Advisors
A.G.P./Alliance Global Partners and Maxim Group LLC acted as financial advisors for the transaction.
- The exercise of warrants signifies investor confidence in SELLAS.
- The issuance of new unregistered warrants indicates potential future investments in the company.
The successful exercise of warrants demonstrates investor interest and support in SELLAS Life Sciences Group's growth and development plans.